



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 705.
Corp. Office: "Strides House", Billekahalli, Bannerghatta Road, Bangalore-560 076.

**UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

Rs.in Lakhs

Sl. No.	Particulars	UNAUDITED				AUDITED
		3 Months ended 30.09.2008	3 Months ended 30.09.2007	9 Months ended 30.09.2008	9 Months ended 30.09.2007	12 Months ended 31.12.2007
1	(a) Net Sales / Income from Operations	16,632.34	10,586.35	44,678.55	31,715.68	39,291.52
	(b) Other Operating Income	2,428.95	566.74	4,120.93	10.62	429.96
	Total Income	19,061.29	11,153.09	48,799.48	31,726.30	39,721.48
2	Expenditure					
	(a) (Increase) / decrease in stock in trade and work in progress	(557.92)	(79.67)	(641.67)	(506.63)	(937.22)
	(b) Consumption of materials	7,995.43	6,006.20	22,758.75	16,859.53	22,892.93
	(c) Purchase of traded goods	2,521.00	503.63	4,017.70	1,067.00	1,293.54
	(d) Employees cost	2,083.67	1,468.27	5,030.66	3,900.70	5,166.94
	(e) Depreciation	460.73	476.58	1,433.10	1,385.23	1,888.79
	(f) Other Expenditure	3,841.33	2,296.86	8,906.64	8,426.88	12,295.67
	Total Expenditure	16,344.24	10,671.87	41,505.18	31,132.71	42,600.65
3	Profit / (Loss) from Operations before Other Income, Interest & Exceptional Items (1-2)	2,717.05	481.22	7,294.30	593.59	(2,879.17)
4	Other Income	-	22.12	-	-	-
5	Profit / (Loss) before Interest & Exceptional Items (3+4)	2,717.05	481.22	7,316.42	593.59	(2,879.17)
6	Interest	923.21	669.65	3,044.25	1,783.03	3,177.49
7	Profit / (Loss) after Interest but before Exceptional Items (5-6)	1,793.84	(188.43)	4,272.17	(1,189.44)	(6,056.66)
8	Exceptional Items					
	- Exchange Fluctuation loss / (gain)	6,953.95	(386.66)	16,616.67	(3,335.68)	(2,407.33)
	- Impairment in Investments	-	-	-	-	8,153.22
9	Profit / (Loss) from Ordinary Activities before tax (7- 8)	(5,160.11)	198.23	(12,344.50)	2,146.24	(11,802.55)
10	Provision for Taxation - Current tax	-	165.00	-	239.00	350.00
	- Deferred tax	-	0.40	-	67.90	(667.00)
	- Fringe benefit tax	7.50	7.91	24.00	20.31	35.80
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	(5,167.61)	24.92	(12,368.50)	1,819.03	(11,521.35)
12	Extraordinary Item	-	-	-	-	-
13	Net Profit / (Loss) for the period	(5,167.61)	24.92	(12,368.50)	1,819.03	(11,521.35)
14	Paid-up Equity Share Capital (Face value of Rs.10/-each)	4,005.00	3,500.40	4,005.00	3,500.40	3,500.40
15	Reserves excluding revaluation reserves	-	-	-	-	16,032.94
16	Earnings per Share (EPS)					
	(a) Basic & Diluted EPS after Extraordinary items for the period (Rs.) (Not Annualised)					
	(i) Basic EPS	(13.12)	(0.18)	(32.86)	4.40	(33.98)
	(ii) Diluted EPS	(13.12)	(0.18)	(32.86)	4.04	(33.98)
	(b) Basic & Diluted EPS before Extraordinary items for the period (Rs.) (Not Annualised)					
	(i) Basic EPS	(13.12)	(0.18)	(32.86)	4.40	(33.98)
	(ii) Diluted EPS	(13.12)	(0.18)	(32.86)	4.04	(33.98)
17	Aggregate of Public shareholding :					
	(a) Number of shares	30,628,013	28,314,149	30,628,013	28,314,149	28,417,595
	(b) Percentage of shareholding	76.47%	80.89%	76.47%	80.89%	81.18%

Notes :

- The above standalone results of the Company were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on October 31, 2008.
- The Statutory Auditors have carried out a limited review of the standalone results.
- During the quarter, Linkace Limited, Cyprus, a wholly owned subsidiary:
 - completed acquisition of controlling interest in Ascent Pharmahealth Limited (formerly Genepharm Australasia Limited), Australia
 - sold 81% stake in Strides Italia S.r.l, Italy.
- During the quarter, Starsmore Limited, Cyprus, a wholly owned subsidiary, ceded controlling interest in the Latin American Ventures and now hold 49% equity in the Ventures for a transition period until June 30, 2009 when the Company intends to sell the remaining 49% to Aspen Pharmacare Holdings Limited, South Africa, for an agreed multiple of EBITDA.
- Consequent to restructuring of Company's South East Asian business with Ascent Pharmahealth Limited (Ascent), Australia, an income of Rs.2,081.48 Lakhs has been recognised on account of assignment of Company's existing independent supply contracts in favour of Strides Singapore Pte Limited, Singapore, a wholly owned subsidiary of Ascent.
- Exchange fluctuation loss / (gain) is on account of restatement of Foreign Currency Convertible Bonds, External Commercial Borrowings and 'Mark to Market' (MTM) loss on derivative and option contracts.
- The Company has one derivative contract on which the determination of liability, if any, is dependant on the occurrence of future uncertain events relating to the foreign exchange rates prevailing in June / July 2010 due to which, a reliable estimate of the losses (if any) cannot be made now. Hence, no provision has been made for an amount of Rs.1,288.82 lakhs at September 30, 2008, being the 'Mark to Market' loss, indicated by the Bank as on September 30, 2008.
- In July 2008, 665,000 options were issued to certain eligible employees under the Strides Arcolab ESOP 2008 Scheme.
- The Company operates exclusively in the Pharmaceuticals business segment and as such there is no reportable segment information as per Accounting Standard 17.
- Investor grievances received and disposed off during the quarter ended September 30, 2008 :
 - Pending complaints at the beginning of the quarter - Nil
 - No. of Complaints received - 11
 - Complaints disposed - 11
 - Complaints unresolved - Nil
- Previous year's / period's figures have been recast / restated wherever necessary to conform to the current year's / period's classification.

For and on behalf of the Board

Bangalore, October 31, 2008

Arun Kumar
Executive Vice Chairman & Managing Director